Chemical Nameevolocumab
Dosage FormInjection (subcutaneous; 140 mg/mL, 420 mg/3.5 mL)
Drug ClassMonoclonal antibodies
CompanyAmgen Inc.
Approval Year2015


  • To reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.
  • As an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C).
  • As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Repatha (evolocumab) Prescribing Information 2019Amgen Inc., Thousand Oaks, CA